Evaluation of pulmonary side effects in prolactinoma patients treated with cabergoline.
Ozlem SoylukZuleyha BingolSema C DogansenNeslihan KurtulmusSeher TanrikuluSema YarmanPublished in: Endokrynologia Polska (2023)
CAB appears to be safe in terms of pulmonary functions with a median cumulative dose of 192 mg in prolactinoma patients.